Tysabri news from FiercePharma
NewsTysabri to get new Euro label
The European Medicines Agency called for an update to product information for Biogen Idec and Elan's multiple sclerosis drug Tysabri, highlighting the risk of a potentially deadly brain infection.... Read more...
Tysabri may deliver 'sustained improvement'
Tysabri may have scored a big plus for drugmakers Biogen Idec and Elan. A trial of the multiple sclerosis treatment showed that it might... Read more...
Biogen, Elan test Tysabri against cancer
Could Tysabri fight cancer as well as it battles multiple sclerosis? Biogen Idec and Elan aim to find out. The companies have given a multiple myeloma patient the first dose in the first clinical... Read more...
FDA, Biogen mull Tysabri label changes
The FDA is huddling with Biogen Idec and Elan on amendments to Tysabri's label. The reason, of course, is the
Icahn snaps up more of Biogen
The Biogen Idec faithful have been preaching "buying opportunity" ever since the company announced two new... Read more...
Judge strikes down Biogen preemption case
Biogen and Elan--along with proponents of preemption--were dealt a setback today as a federal judge declined to transfer a case from Massachusetts to a federal court in Iowa. The lawsuit stems from... Read more...
Analysts: Tysabri scrips will suffer
When Biogen Idec announced last week that a potentially fatal brain infection had cropped up again in Tysabri... Read more...
Biogen: Tysabri patients have PML
Biogen Idec CEO James Mullen predicted it, and now it's happened: Two Tysabri patients have come down with the potentially fatal brain infection, progressive multifocal leukoencephalopathy, or PML,... Read more...
Biogen CEO: Tysabri to reach $1B in 2008
Two years ago this week, Biogen Idec relaunched Tysabri, the multiple sclerosis and Crohn's disease treatment, after a safety scare. Now, the drug is shaping up to be a blockbuster, the Wall Street... Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring... Read more...
| Press ReleasesEU Panel Recommends Update For Elan, Biogen's Tysabri LabelEU Panel Recommends Update For Elan, Biogen's Tysabri Label ZURICH -(Dow Jones)- European Medicines Agency, an advisory body to the European drugs regulator, said Thursday it recommends an update of Read more >> TYSABRI® DEMONSTRATES SUSTAINED IMPROVEMENT IN FUNCTIONAL OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS ACCORDING TO NEW POST-HOC ANALTYSABRI® DEMONSTRATES SUSTAINED IMPROVEMENT IN FUNCTIONAL OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS ACCORDING TO NEW POST-HOC ANALYSIS TYSABRI is the Only Marketed MS Treatment to Show Both Read more >> First Multiple Myeloma Patient TreatedElan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology First Multiple Myeloma Patient Treated CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 5, 2008--Elan Read more >> FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab)FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab) Information for Healthcare Professionals Natalizumab Injection for Intraveneous Use (marketed as Tysabri) Read more >> |
Get more Tysabri coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
